"The investment is through a mix of primary (Rs 120 crore) and secondary (Rs 30 crore) sale," said Tushar Korday director, Emil Pharmaceutical. "The investment outlay may increase in the near future," Korday added, but the company did not disclose the size of the minority stake.
